Reported herein is a visible‐light‐mediated radical approach to the α‐alkylation of ketones. This method exploits the ability of a nucleophilic organocatalyst to generate radicals upon SN2‐based activation of alkyl halides and blue light irradiation. The resulting open‐shell intermediates are then intercepted by weakly nucleophilic silyl enol ethers, which would be unable to directly attack the alkyl
[EN] METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS<br/>[FR] METHODE D'UTILISATION DE DERIVES DU PYRANOINDOLE POUR TRAITER UNE INFECTION PAR LE VIRUS DE L'HEPATITE C
申请人:WYETH CORP
公开号:WO2003099275A1
公开(公告)日:2003-12-04
The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising containing the mammal with an effective amount of a compound of the formula: Wherein substitutions at R1, R2, R3-R12, and Y are set forth in the specification.
Verfahren zur Herstellung von 3-Alkoxyphthalsäuredinitrilen
申请人:Bayer Chemicals AG
公开号:EP1424323A1
公开(公告)日:2004-06-02
Verfahren zur Herstellung von 3-Alkoxyphthalsäuredinitrilen der Formel I
worin
Rfür gegebenenfalls substituiertes Alkyl oder Cycloalkyl steht,
durch Umsetzung von 3-Nitrophthalsäuredinitril mit einem Alkohol ROH, in einem von den Reaktanden verschiedenen Lösungsmittel in Gegenwart einer Base, dadurch gekennzeichnet, dass entweder
a) 3-Nitrophthalsäuredinitril und die Base in einem Lösungsmittel vorgelegt werden und der Alkohol ROH der Vorlage zugegeben wird, oder
b) der Alkohol ROH und die Base in einem Lösungsmittel vorgelegt werden und 3-Nitrophthalsäuredinitril der Vorlage zugegeben wird.
Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus
申请人:Wyeth
公开号:US20040082643A1
公开(公告)日:2004-04-29
The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of a compound of the formula:
1
Wherein substitutions at R
1
, R
2
, R
3
-R
12
, and Y are set forth in the specification.
Substituted pyrimidines containing acidic groups as TLR7 modulators
申请人:Apros Therapeutics, Inc.
公开号:US10287253B2
公开(公告)日:2019-05-14
The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of viral infections and cancers. One aspect of the present disclosure relates to a compound represented by Formula 1: